WHO ICTRP trial
A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate…
NL-OMON44053 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON44053 |
|---|---|
| Public title | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis. |
| Scientific title | A Long-Term, Open-Label, Safety and Efficacy Study of Cysteamine Bitartrate Delayed-release Capsules (RP103) in Patients with Cystinosis. - RP103-04 |
| Primary sponsor | Raptor Pharmaceuticals Europe BV |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 3 |
| Countries | The Netherlands |
| Conditions | Nephropathic cystinosis; metabolic disorder in which the transport of cystine out of the lysosomes is abnormal;10000546;Nephropathic cystinosis; metabolic disorder in which the transport of cystine out of the lysosomes is abnormal |
| Interventions | This is an open-label study during which patients will receive RP103 for up to 8 years. ;Cysteamine Bitartrate (INN : mercaptamine bitartrate) Delayed-release Capsules;Long-term;Nephropathic Cystinosis;Open-label |
| Registration date | Jan 21, 2016 |
| Target size | 5 |
| Secondary IDs | 2010-018365-34;NCT01197378;NL33066.091.10 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: